FBRX
Forte Biosciences, Inc.
$17.00
+8.49%
$320.9M
No data for this timeframe.
Vol
Market Cap$320.9M
Cap SizeSmall Cap
Inst. Holders6 funds
Inst. Value$27.3M
Inst. Activity5 buys / 1 sells
SEC Reports7
Recent Activity
Jun 8, 2026
SEC
Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (
S-3/A — Impact 6/10
Jun 5, 2026
SEC
Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to $500,000,000 in sec
S-3 — Impact 6/10
Jun 3, 2026
Event
Nalocet
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE AND ACETAMINOPHEN TABLETS Addictio
Jun 2, 2026
SEC
Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended
8-K — Impact 3/10
May 29, 2026
Insider
Brun Scott C. sold 18,353 shares
Director @ $0.00 ($0.00)
May 29, 2026
Insider
Kornfeld Steven sold 18,353 shares
Director @ $0.00 ($0.00)
May 29, 2026
Insider
GRYSKA DAVID W sold 18,353 shares
Director @ $0.00 ($0.00)
Inst.
FMR LLC — ADD
310,965 shares ($8.5M)
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$63.75 (Nov 2025)
Current $17.00
Low $54.00
Median $63.00
High $75.00
4 analysts
$54.00
$75.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 25, 2025 | Evercore ISI Group | INITIATE | Outperform |
| Nov 17, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Aug 18, 2025 | Guggenheim | INITIATE | Buy |
| Aug 15, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jun 24, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.01 ▲ +4.0% | $-1.11 — $-0.89 | -5% YoY | 4 |
| Next Q | $-1.00 ▲ +3.4% | $-1.16 — $-0.90 | -2% YoY | 4 |
| Current FY | $-4.01 | $-4.67 — $-3.22 | 15% YoY | 5 |
| Next FY | $-4.14 | $-5.36 — $-2.89 | -3% YoY | 5 |
Latest Reports
BEARISH
S-3/A
6/10
Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (
Jun 8, 2026
BEARISH
S-3
6/10
Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to $500,000,000 in sec
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $15.9M | DOUBLED |
| FMR LLC | $8.5M | ADD |
| MORGAN STANLEY | $1.9M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $867.4K | NEW |
| BANK OF AMERICA CORP | $108.3K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Brun Scott | A | $0.00 |
| May 29, 2026 | Kornfeld Steven | A | $0.00 |
| May 29, 2026 | GRYSKA DAVID | A | $0.00 |
| May 29, 2026 | VINCENT RICHARD | A | $0.00 |
| May 29, 2026 | Kapoor Shivpreet | A | $0.00 |
6 institutional holders with $27.3M total value (1,000,041 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 582,263 | $15.9M | 58.2% | DOUBLED +447.4% |
| 2 | FMR LLC | 310,965 | $8.5M | 31.1% | ADD +27.2% |
| 3 | MORGAN STANLEY | 70,531 | $1.9M | 7.1% | DOUBLED +46609.3% |
| 4 | TWO SIGMA INVESTMENTS, LP | 31,808 | $867.4K | 3.2% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 3,972 | $108.3K | 0.4% | ADD +25.8% |
| 6 | WELLS FARGO & COMPANY/MN | 502 | $13.7K | 0.1% | DOUBLED +25000.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 244,400 | 310,965 | +27.2% | $8.5M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 151 | 70,531 | +46609.3% | $1.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 31,808 | — | $867.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 3,158 | 3,972 | +25.8% | $108.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 2 | 502 | +25000.0% | $13.7K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 16,200 | 0 | -100.0% | $0.00 | 2025-Q4 |
| FMR LLC | NEW | — | 244,400 | — | $3.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 16,200 | — | $243.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 55 | 3,158 | +5641.8% | $47.4K | 2025-Q3 |
| UBS Group AG | DOUBLED | 1 | 1,560 | +155900.0% | $23.4K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 88,951 | 486,919 | +447.4% | $6.3M | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 527 | 1 | -99.8% | $13.00 | 2025-Q2 |
| VANGUARD GROUP INC | DOUBLED | 26,394 | 88,951 | +237.0% | $690.3K | 2025-Q1 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Brun Scott C. | Director | A | 18,353 | $0.00 | $0.00 |
| May 29, 2026 | Kornfeld Steven | Director | A | 18,353 | $0.00 | $0.00 |
| May 29, 2026 | GRYSKA DAVID W | Director | A | 18,353 | $0.00 | $0.00 |
| May 29, 2026 | VINCENT RICHARD G | Director | A | 18,353 | $0.00 | $0.00 |
| May 29, 2026 | Kapoor Shivpreet Singh | Director | A | 18,353 | $0.00 | $0.00 |
| May 29, 2026 | Doberstein Stephen K | Director | A | 18,353 | $0.00 | $0.00 |
| Apr 1, 2026 | Riley Antony A | CHIEF FINANCIAL OFFICER | M | 375 | $0.00 | $0.00 |
| Apr 1, 2026 | Wagner Paul A. | SEE REMARKS | M | 1,250 | $0.00 | $0.00 |
| Apr 1, 2026 | Wagner Paul A. | SEE REMARKS | F | 98 | $24.86 | $2.4K |
| Apr 1, 2026 | Wagner Paul A. | SEE REMARKS | M | 1,250 | $0.00 | $0.00 |
| Apr 1, 2026 | Riley Antony A | CHIEF FINANCIAL OFFICER | F | 134 | $24.86 | $3.3K |
| Apr 1, 2026 | Riley Antony A | CHIEF FINANCIAL OFFICER | M | 375 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 1 mixed, 2 neutral. Avg impact: 5.4/10.
BEARISH
S-3/A
6/10
Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $
Jun 8, 2026
BEARISH
S-3
6/10
Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to
Jun 5, 2026
NEUTRAL
8-K
3/10
Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders
Jun 2, 2026
MIXED
8-K
6/10
Forte Biosciences reported Q1 2026 net loss of $1.24/share, wider than the $0.98 consensus miss, wit
May 14, 2026
BEARISH
8-K
7/10
Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates,
Apr 21, 2026
NEUTRAL
8-K
5/10
Forte Biosciences announced a $150 million public offering of 5.7 million shares at $26.27 per share
Apr 9, 2026
BEARISH
424B5
5/10
Forte Biosciences is conducting a follow-on public offering of common stock to raise capital, citing
Apr 8, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2025): 91% buy across 11 analysts — 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$63.75 mean target (Nov 2025)
$54.00 Low
$75.00 High
| Metric | Value |
|---|---|
| Current Price | $17.00 |
| Target Low | $54.00 |
| Target Mean | $63.75 |
| Target Median | $63.00 |
| Target High | $75.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.01 | $-1.11 | $-0.89 | -5.0% | +4.0% | 2↑ 2↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-1.00 | $-1.16 | $-0.90 | -1.5% | +3.4% | 3↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-4.01 | $-4.67 | $-3.22 | 14.9% | — | 4↑ 1↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-4.14 | $-5.36 | $-2.89 | -3.3% | — | 3↑ 2↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.008 | |
| 7d ago | $-1.050 | +0.042 |
| 30d ago | $-1.050 | +0.042 |
| 60d ago | $-0.760 | -0.248 |
| 90d ago | $-0.830 | -0.178 |
9 analyst firms have rated this stock: 3 upgrades, 5 downgrades, 9 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 25, 2025 | Evercore ISI Group | INITIATE | — | Outperform |
| Nov 17, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Aug 18, 2025 | Guggenheim | INITIATE | — | Buy |
| Aug 15, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jun 24, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Apr 1, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 21, 2025 | TD Cowen | INITIATE | — | Buy |
| Dec 4, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| Nov 15, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| Aug 19, 2024 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 30, 2024 | Brookline Capital | INITIATE | — | Buy |
| Apr 8, 2024 | Ladenburg Thalmann | UPGRADE | Neutral | Buy |
| Sep 20, 2021 | Chardan Capital | UPGRADE | Sell | Neutral |
| Sep 3, 2021 | Brookline Capital | DOWNGRADE | Buy | Hold |
| Sep 3, 2021 | Chardan Capital | DOWNGRADE | Buy | Sell |
| Sep 3, 2021 | Ladenburg Thalmann | DOWNGRADE | Buy | Neutral |
| Sep 3, 2021 | B. Riley Securities | DOWNGRADE | Buy | Neutral |
| Sep 3, 2021 | Truist Securities | DOWNGRADE | Buy | Hold |
| May 14, 2021 | B. Riley Securities | INITIATE | — | Buy |
| Mar 26, 2021 | Citigroup | INITIATE | — | Buy |
| Mar 17, 2021 | Chardan Capital | MAINTAIN | — | Buy |
| Sep 24, 2020 | Chardan Capital | MAINTAIN | — | Buy |
| Sep 10, 2020 | Chardan Capital | MAINTAIN | — | Buy |
| Aug 28, 2020 | Brookline Capital | INITIATE | — | Buy |
| Aug 28, 2020 | Chardan Capital | UPGRADE | Neutral | Buy |
| Aug 25, 2020 | Truist Securities | INITIATE | — | Buy |
| Jun 22, 2020 | Ladenburg Thalmann | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
FDA
Nalocet
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of oxycodone
May 13, 2026
earnings_calendar
FBRX Q1 2026 Earnings Scheduled — 2026-05-13
Mar 26, 2026
earnings_calendar
FBRX Q4 2025 Earnings After Market Close — 2026-03-26